
Leap Therapeutics identifies DKK1 as predictive marker in cancer trial
A Phase 2 study of the antibody sirexatamab has revealed that patients with high baseline levels of the protein DKK1 show significantly improved survival rates when treated with the drug, offering a potential path forward for targeting aggressive metastatic colorectal cancer despite missing primary endpoints in the broader trial population.
























